DNA damage repair in glioblastoma: current perspectives on its role in tumour progression, treatment resistance and PIKKing potential therapeutic targets

被引:15
作者
Lozinski, Mathew [1 ,2 ,3 ]
Bowden, Nikola A. [2 ,3 ,4 ]
Graves, Moira C. [2 ,3 ,4 ]
Fay, Michael [2 ,3 ,5 ]
Tooney, Paul A. [1 ,2 ,3 ]
机构
[1] Univ Newcastle, Fac Hlth & Med, Sch Biomed Sci & Pharm, Newcastle, NSW, Australia
[2] Univ Newcastle, Ctr Drug Repurposing & Med Res, Newcastle, NSW, Australia
[3] Hunter Med Res Inst, Newcastle, NSW, Australia
[4] Univ Newcastle, Fac Hlth & Med, Sch Med & Publ Hlth, Newcastle, NSW, Australia
[5] Genesis Canc Care, Gateshead, NSW, Australia
关键词
Glioblastoma; DNA damage response; DNA repair; Treatment resistance; PIKK inhibitor; Blood-brain barrier; MGMT PROMOTER METHYLATION; STRAND BREAK REPAIR; CENTRAL-NERVOUS-SYSTEM; RANDOMIZED PHASE-III; STEM-LIKE CELLS; MISMATCH-REPAIR; TEMOZOLOMIDE RESISTANCE; MUTATIONAL BURDEN; CANCER-CELLS; ATAXIA-TELANGIECTASIA;
D O I
10.1007/s13402-021-00613-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The aggressive, invasive and treatment resistant nature of glioblastoma makes it one of the most lethal cancers in humans. Total surgical resection is difficult, and a combination of radiation and chemotherapy is used to treat the remaining invasive cells beyond the tumour border by inducing DNA damage and activating cell death pathways in glioblastoma cells. Unfortunately, recurrence is common and a major hurdle in treatment, often met with a more aggressive and treatment resistant tumour. A mechanism of resistance is the response of DNA repair pathways upon treatment-induced DNA damage, which enact cell-cycle arrest and repair of DNA damage that would otherwise cause cell death in tumour cells. Conclusions In this review, we discuss the significance of DNA repair mechanisms in tumour formation, aggression and treatment resistance. We identify an underlying trend in the literature, wherein alterations in DNA repair pathways facilitate glioma progression, while established high-grade gliomas benefit from constitutively active DNA repair pathways in the repair of treatment-induced DNA damage. We also consider the clinical feasibility of inhibiting DNA repair in glioblastoma and current strategies of using DNA repair inhibitors as agents in combination with chemotherapy, radiation or immunotherapy. Finally, the importance of blood-brain barrier penetrance when designing novel small-molecule inhibitors is discussed.
引用
收藏
页码:961 / 981
页数:21
相关论文
共 192 条
[1]   Recruitment of ATR to sites of ionising radiation-induced DNA damage requires ATM and components of the MRN protein complex [J].
Adams, KE ;
Medhurst, AL ;
Dart, DA ;
Lakin, ND .
ONCOGENE, 2006, 25 (28) :3894-3904
[2]   Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain [J].
Agarwal, Sagar ;
Sane, Ramola ;
Oberoi, Rajneet ;
Ohlfest, John R. ;
Elmquist, William F. .
EXPERT REVIEWS IN MOLECULAR MEDICINE, 2011, 13 :e17
[3]   Checkpoint inhibitor failure in hypermutated and mismatch repair-mutated recurrent high-grade gliomas [J].
Ahmad, Haroon ;
Fadul, Camilo E. ;
Schiff, David ;
Purow, Benjamin .
NEURO-ONCOLOGY PRACTICE, 2019, 6 (06) :424-427
[4]   A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells [J].
Ahmed, Eroje M. ;
Bandopadhyay, Gagori ;
Coyle, Beth ;
Grabowska, Anna .
CELLULAR ONCOLOGY, 2018, 41 (03) :319-328
[5]   Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy [J].
Albarakati, Nada ;
Abdel-Fatah, Tarek M. A. ;
Doherty, Rachel ;
Russell, Roslin ;
Agarwal, Devika ;
Moseley, Paul ;
Perry, Christina ;
Arora, Arvind ;
Alsubhi, Nouf ;
Seedhouse, Claire ;
Rakha, Emad A. ;
Green, Andrew ;
Ball, Graham ;
Chan, Stephen ;
Caldas, Carlos ;
Ellis, Ian O. ;
Madhusudan, Srinivasan .
MOLECULAR ONCOLOGY, 2015, 9 (01) :204-217
[6]  
[Anonymous], FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication
[7]   Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy [J].
Auffinger, B. ;
Tobias, A. L. ;
Han, Y. ;
Lee, G. ;
Guo, D. ;
Dey, M. ;
Lesniak, M. S. ;
Ahmed, A. U. .
CELL DEATH AND DIFFERENTIATION, 2014, 21 (07) :1119-1131
[8]   Involvement of ATM in homologous recombination after end resection and RAD51 nucleofilament formation [J].
Bakr, A. ;
Oing, C. ;
Koecher, S. ;
Borgmann, K. ;
Dornreiter, I. ;
Petersen, C. ;
Dikomey, E. ;
Mansour, W. Y. .
NUCLEIC ACIDS RESEARCH, 2015, 43 (06) :3154-3166
[9]   Characteristics of compounds that cross the blood-brain barrier [J].
Banks, William A. .
BMC NEUROLOGY, 2009, 9
[10]   DNA damage signalling guards against activated oncogenes and tumour progression [J].
Bartek, J. ;
Bartkova, J. ;
Lukas, J. .
ONCOGENE, 2007, 26 (56) :7773-7779